Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice. - Wikidata - awgldk - TriplyDB

Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice.

Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice.

http://www.wikidata.org/entity/Q37439729

about

Nitrooleic Acid Attenuates Lipid Metabolic Disorders and Liver Steatosis in DOCA-Salt Hypertensive Mice.Nitric oxide in liver diseases.Nitro-fatty acids in cardiovascular regulation and diseases: characteristics and molecular mechanisms.PGE2, Kidney Disease, and Cardiovascular Risk: Beyond Hypertension and Diabetes.Protection of nitro-fatty acid against kidney diseases.PPARγ Agonist Rosiglitazone Suppresses Renal mPGES-1/PGE2 Pathway in db/db Mice.Evaluation of 10-Nitro Oleic Acid Bio-Elimination in Rats and Humans.New Insights into the PPAR γ Agonists for the Treatment of Diabetic Nephropathy.Renin-angiotensin system within the diabetic podocyte.Designing drugs that combat kidney damage.Anti-Fibrotic Effect of Losartan, an Angiotensin II Receptor Blocker, Is Mediated through Inhibition of ER Stress via Up-Regulation of SIRT1, Followed by Induction of HO-1 and Thioredoxin.Nitro-oleic acid is a novel anti-oxidative therapy for diabetic kidney disease.Inflammatory signaling and metabolic regulation by nitro-fatty acids.Profile of Arachidonic Acid-Derived Inflammatory Markers and Its Modulation by Nitro-Oleic Acid in an Inherited Model of Amyotrophic Lateral Sclerosis.

P2860

Q35227098-81D4971F-6ACC-4224-940C-048E1D822CDD Q35940869-C467E227-FB53-4054-B082-31A0C0C328C8 Q36565424-DF8E4319-FDD3-4DAE-9142-6AB5ACCA6286 Q36624751-56FEC091-11BC-4D15-8714-2EEE4BE63DE7 Q36810720-8D7931DA-D1A1-4325-8778-1DED6129FB11 Q37482379-23D4E988-C8C9-40BF-A10F-1A4E95BFA314 Q37560854-394FA6B7-E24C-4EAD-AE4F-466ABA385D3E Q37590946-41F52D17-0452-4663-9EE3-4984F2410D3A Q38262105-1DEC7393-2D38-43F3-B748-AAC3E7B52927 Q38404587-BE528199-CE71-4AB6-A232-646230165054 Q42100753-0A7F84EC-911A-491F-8CF5-8FB782732A1C Q42756932-AB77F2D5-9840-4F28-91E3-6D2E39256535 Q52631728-054F03A6-F6BD-465F-BF9B-B4A1B014F6E0 Q54972559-E7DAF4CD-5707-4A11-B75C-F57CF2022628

P2860

Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice.

http://www.wikidata.org/entity/Q37439729

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 14 August 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice.

@en

Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice.

@nl

type

label

Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice.

@en

Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice.

@nl

prefLabel

Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice.

@en

Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice.

@nl

P1433

Q37439729-B312EC58-8461-4273-B28B-C4C2AE0BC808

P1476

Q37439729-35296BF4-F4D8-4AE6-B3CE-7678E6E00770

P2093

Q37439729-49EA7149-078D-4CFF-93DF-F578B3347723

Q37439729-7B0F3C64-EE6F-4C5A-935A-FD621772BEE1

Q37439729-A7C8C33D-EC7A-4A77-8C1A-BEE45B9CAFBC

Q37439729-AD7E5FBC-D66D-4B76-BE2F-F5C6FCD7C814

Q37439729-D195A7CE-D09F-444C-A05C-77E7110B8EDE

Q37439729-F2B0DC9E-73FC-4DCC-A9E4-9138BA21B7AB

Q37439729-F7A235BB-2EC4-4163-9703-70F918D75F81

P2860

Q37439729-054BE72C-B42A-4FC4-BF90-A804310D1D57

Q37439729-07FC5A92-AC28-4DFA-99D9-04E3FA3646A6

Q37439729-096F77CE-2D58-4033-998A-B2246444C3FC

Q37439729-0B2609D3-1428-4E5B-A56D-131926B78895

Q37439729-0D510FE6-1490-4494-ACA2-587AFC3A5123

Q37439729-0DD8E99B-2F52-4325-990B-FE308E064D9E

Q37439729-15DC183C-C9D8-4C45-8320-F9CBA724A515

Q37439729-1B957F52-505C-46D4-A431-CD471114F33C

Q37439729-2F29A740-0CD1-4B2A-9FFE-FD555292D8C4

Q37439729-38AEC0FE-B235-4894-9166-8AFAD420754A

P304

Q37439729-4996B8D6-3835-46BB-BA7B-30FB006E0E59

P31

Q37439729-0883199B-6063-4811-BF35-8FC2E23B0F5F

P356

Q37439729-A33E39E1-F9F3-42CC-B5E6-CEE27AFEE38C

P433

Q37439729-E5560EC4-2353-4D0B-8C3E-D8CCE11EDD3A

P478

Q37439729-08A3EEEB-90C4-4420-B437-A31461197D5C

P577

Q37439729-FF73ADA1-4978-4EF4-B775-0A337A5EA9DB

P5875

Q37439729-E42117E8-45A5-46C9-93D6-2DC4711445F7

P698

Q37439729-3C86B740-F52E-43E6-B1AE-81C2E770148D

P932

Q37439729-FA21AC11-44FC-4FD8-AEBE-434D82F2DA30

P356

AJPRENAL.00157.2013

P1433

American Journal of Physiology - Renal Physiology

P1476

Combined losartan and nitro-oleic acid remarkably improves diabetic nephropathy in mice.

@en

P2093

Gang Liu

http://www.w3.org/2001/XMLSchema#string

Maicy Downton

http://www.w3.org/2001/XMLSchema#string

Shanshan Liu

http://www.w3.org/2001/XMLSchema#string

Tianxin Yang

http://www.w3.org/2001/XMLSchema#string

Yaomin Du

http://www.w3.org/2001/XMLSchema#string

Ying Liu

http://www.w3.org/2001/XMLSchema#string

Zhanjun Jia

http://www.w3.org/2001/XMLSchema#string

P2860

Biochemistry and molecular cell biology of diabetic complications

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

Oxidative stress as a major culprit in kidney disease in diabetes

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

Convergence of nitric oxide and lipid signaling: anti-inflammatory nitro-fatty acids.

Human haem oxygenase-1 induction by nitro-linoleic acid is mediated by cAMP, AP-1 and E-box response element interactions.

Nitrated fatty acids: Endogenous anti-inflammatory signaling mediators

Activation of vascular endothelial nitric oxide synthase and heme oxygenase-1 expression by electrophilic nitro-fatty acids.

Nitro-oleic acid protects against endotoxin-induced endotoxemia and multiorgan injury in mice

Electrophilic nitro-fatty acids: anti-inflammatory mediators in the vascular compartment.

P304

F1555-62

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1152/AJPRENAL.00157.2013

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

305

http://www.w3.org/2001/XMLSchema#string

P577

2013-08-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

255955342

http://www.w3.org/2001/XMLSchema#string

P698

23946292

http://www.w3.org/2001/XMLSchema#string

P932

3882366

http://www.w3.org/2001/XMLSchema#string